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Purpose: The purpose of this study is to make a prospective evaluation of the effect of timolol 
0.1% eye gel on short-term intraocular pressure (IOP) after an intravitreal injection (IVI) of 
ranibizumab.
Participants and methods: One hundred and fifty eyes of 150 IVI-naïve patients with macular 
edema caused by various pathological conditions (age-related macular degeneration, central or 
branch retinal vein occlusion, and diabetic retinopathy) were scheduled to undergo an IVI of 
ranibizumab (0.5 mg/0.05 cc). The patients were randomly divided into three groups: 50 were 
not treated with timolol before the IVI (group 1); 50 received an instillation of timolol 0.1% 
eye gel the evening before the IVI (group 2); and 50 received an instillation of timolol 0.1% 
eye gel 2 hours before the IVI (group 3). The incidence of clinically significant intraocular 
hypertensive spikes (25 mmHg and 40 mmHg) was then assessed.
Results: Our findings showed that mean IOP at baseline was significantly higher than at both 
5 and 60 minutes after IVI (P0.01). Spikes of 25 mmHg were recorded at either time in 
27 patients (54%) in group 1, 23 patients (44%) in group 2, and 24 patients (48%) in group 3. 
None of the between-group differences were significant. Spikes of 40 mmHg (which were 
only detected 5 minutes after IVI) were recorded in nine (18%), eight (16%), and one patient 
(2%) in groups 1, 2, and 3, respectively. The only significant difference was between the control 
and group 3 (P=0.012).
Conclusion: An increase in IOP after antivascular endothelial growth factor IVI is a frequent 
complication. The prophylactic use of timolol 0.1% gel effectively reduced the mean IOP when 
administered 2 hours before IVI and was also effective in preventing dangerous IOP spikes 
of 40 mmHg. It is therefore recommended before IVIs as a means of preventing emergency 
procedures and preserving the health of the optic nerve.
Keywords: macular edema, pressure spikes, anti-VEGF therapy, pressure-lowering medication
Introduction
Intravitreal antivascular endothelial growth factor (VEGF) injections are currently 
used to treat macular edema and suppress neovascularization in the case of many eye 
diseases.1–3 Given the increase in the indications for anti-VEGF agents and the fact 
that a larger number of patients being treated usually require repeated intravitreal 
injections (IVIs), it is important to identify any adverse effects.
The most frequent complications of IVIs are subconjunctival and vitreal hemorrhages, 
corneal edema, conjunctival scars, retinal tears and detachment, lens damage, develop-
ment of cataracts, choroidal rupture, ocular hypertension, and endophthalmitis.4,5 The 
injection of anti-VEGF fluid into the vitreous cavity is expected to increase the intraocular 
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pressure (IOP),6–10 and although this is usually transient, it 
occasionally persists.7,9–14 Both MARINA and ANCHOR tri-
als found transient post-IVI increases in IOP in the treatment 
groups, although very few patients experienced an increase 
of 40 mmHg; however, the injection protocols did not require 
IOP measurements within 1 hour of the injections, and so the 
increase in IOP during this time was not reported.15,16
We evaluated the short-term effect of topical prophy-
laxis with timolol 0.1% (Timogel® preservative-free eye 
gel, THEA, Clermont-Ferrand, France) on short-term IOP 
changes in patients receiving IVIs of ranibizumab (Lucentis®; 
Novartis International AG, Basel, Switzerland).
Participants and methods
This prospective study included all the patients who were 
referred to the Eye Unit of Melegnano Hospital (Milan, 
Italy) between September 2013 and September 2014. All 
the procedures performed in this study involving human 
participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with 
the 1964 Declaration of Helsinki and its later amendments 
or comparable ethical standards. The ethics approval was 
deemed not necessary by the Ethics Committe of Melegnano 
Hospital, in accordance to Italian law as our work did not 
involve particular changes in existing procedures in our 
clinical practice, and as the drug used is not an experimental 
product, but widely used and already used at our hospital.
One hundred and fifty IVI-naïve patients were affected by 
macular edema caused by age-related macular degeneration, 
central or branch retinal vein occlusion, or diabetic retin-
opathy and were scheduled for treatment with ranibizumab 
(Lucentis 0.5 mg/0.05 cc).
The patients were randomly divided into three groups: 
50 were not treated with timolol before the IVI (group 1); 50 
received an instillation of timolol 0.1% eye gel the evening 
before the IVI (group 2); and 50 received an instillation 
of timolol 0.1% eye gel 2 hours before the IVI (group 3). 
The exclusion criteria were a history of glaucoma, ocular 
hypertension or treatment with an IOP-lowering medica-
tion, intraocular surgery in the previous 3 months, corneal 
diseases, or active intraocular inflammation.
All the patients underwent a complete ophthalmic exami-
nation including the measurement of best corrected visual 
acuity, a study of the oculi of the anterior segment and fundus, 
angiography with fluorescein (Heidelberg Retina Angio-
graph; Heidelberg Engineering, Heidelberg, Germany), and 
optical coherence tomography (Spectral optical coherence 
tomography/scanning laser ophthalmoscope; OPKO/OTI, 
Miami, FL, USA).
All the IVIs were performed under topical anesthesia in 
operating rooms by two surgeons who were familiar with 
the procedure; both the surgeons used the same technique 
and were blinded to the group assignments of the patients. 
Ranibizumab was administered using a 30-gauge needle 
following the international guidelines for IVIs.17 Prior 
to receiving the injection, the patients gave their written 
informed consent after being informed about its use, efficacy, 
and complications; none of them received steroid medica-
tions before or immediately after IVI, and none required 
paracentesis.
IOP was measured 15 days before, 5 minutes, and 1 hour 
after the IVI using Goldmann applanation tonometry (Model 
AT 900 C/M; Haag-Streit, Switzerland) with the patients in 
a sitting position, and spikes of 25 mmHg and 40 mmHg 
were recorded.
The between-group differences in mean IOP at the two 
post-IVI times were analyzed using analysis of variance for 
repeated measures (a multivariate mixed model including 
the treatment group and the time of measurement as fixed 
factors and the subject as the random grouping factor) in order 
to determine the correlations between the measurements made 
in the same subject. The mean IOP values in each group were 
compared at each time point, and the values at the two time 
points were compared within each group. The P-values were 
obtained by comparing the marginal mean values obtained 
from a single linear model (using the R package lsmeans).
Subsequently, logistic univariate or multivariate regres-
sion was used to analyze the incidence of hypertensive 
spikes. In this analysis, binary coding was used to identify 
all the subjects whose IOP was 25 or 40 mmHg at either 
time after the injection, and these binary variables were then 
modeled as a binomial response within the framework of a 
classical logistic regression from which the odds ratios were 
derived. This therefore, tested the probability of the subjects 
in each group having an IOP value that was higher than the 
specified threshold of 25 mmHg (Table 1) or 40 mmHg 
(Table 2) rather than the differences in frequencies. Spike 
frequencies are given in Table 1 in order to make it easier to 
interpret the results. Each treatment group were compared 
with the control group as the reference group.
Results
The mean age (± standard deviation) of the patients in groups 
1, 2, and 3 was 71.4 (±9.6), 71.6 (±9.5), and 70.3 (±9.2) years, 
respectively. The percentage of females (60%, 54%, and 
52%, respectively) and pseudophakic eyes (60%, 64%, and 
60%, respectively) was similar in the three groups (Table 3), 
as was the mean baseline IOP and the trends of IOP.
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The highest mean IOP values in groups 1, 2, and 3 
were recorded 5 minutes after IVI (29.3±12, 28.3±9.9, and 
25.5±6.4 mmHg, respectively), which were higher than at base-
line (15.1±1.6, 15.3±1.6, and 15.5±1.9 mmHg, respectively) 
and after 60 minutes (18.7±5.4, 18.8±5.9, and 17.3±3.9 mmHg, 
respectively). At each time point, mean IOP was significantly 
higher than that at baseline (P0.01), except in group 3 
(P=0.23). None of the patients required paracentesis to control 
the hypertensive spikes. Mean IOP after 5 minutes was 13% 
lower in group 3 (which received timolol 0.1% gel 2 hours 
before the IVI) than in the control group (P=0.008) (Table 4).
Table 3 shows the incidence of clinically significant 
intraocular hypertensive spikes (25 or 40 mmHg) 
in the three groups. The number of patients with spikes 
of 25 mmHg was similar in groups 1, 2, and 3 (n=27, 54%; 
n=23, 44%; n=24, 48%, respectively), which was slightly 
higher in the control group. Spikes of 40 mmHg were 
only detected after 5 minutes, and their incidence was more 
heterogeneous (n=9, 18%; n=8, 16%; n=1, 2%, respectively), 
the lowest being found in group 3. The significance of the dif-
ference in the number of hypertensive spikes was tested using 
univariate and multivariate logistic regression (“Materials 
and methods” section for details). A series of univariate 
analyses tested the possible associations between the control 
variables (age, sex, concomitant diseases, and pseudophakia) 
and the incidence of hypertensive spikes (Tables 2 and 5), and 
the control variables that proved to be significant at univariate 
analysis were included in the multivariate analysis (only sex 
was excluded). The multivariate logistic regression showed 
no significant difference between the two treated groups 
and the controls in terms of preventing IOP from increasing 
to 25 mmHg at any time. Only pseudophakia had a signifi-
cant protective effect against spikes of 25 mmHg (hazard 
ratio [HR] =0.2, P0.01).
The same analysis was used to analyze the differences 
in the number of hypertensive spikes of 40 mmHg and 
showed that the administration of timolol 0.1% 2 hours 
before the procedure significantly reduced them in compari-
son with the control group (P=0.012). The administration of 
timolol 0.1% the evening before the procedure did not lead 
to any significant advantage (P=0.73). Pseudophakia was 
significantly associated with the incidence of IOP spikes 
of 40 mmHg (P=0.0002), against which it was highly 
protective (HR =0.01), whereas age was a major risk factor 
(HR =4.74, P=0.047) (Tables 2 and 5).
Discussion
The MARINA and ANCHOR studies of the efficacy of anti-
VEGF IVIs initially found no sustained increase in IOP,15,16 
but it is known that high IOP levels are a frequent complication 
Table 1 spike occurrence
Variable Arm After 5 minutes After 60 minutes At any time
Patients with spike 25 mmhg (n [%]) Untreated
Timogel given the evening before
Timogel given 2 hours before
27 (54.0)
22 (44.0)
24 (48.0)
6 (12.0)
8 (16.0)
1 (2.0)
27 (54.0)
23 (46.0)
24 (48.0)
Patients with spike 40 mmhg (n [%]) Untreated
Timogel given the evening before
Timogel given 2 hours before
9 (18.0)
8 (16.0)
1 (2.0)
–
–
–
9 (18.0)
8 (16.0)
1 (2.0)
Abbreviation: –, not included.
Table 2 association with spike 40 mmhg occurrence after 5 minutes
Variable Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
age (for each 10-year increase) 0.45 (0.26–0.77) 0.004 4.74 (1.02–22.0) 0.047
sex
Female (reference)
Male
1
0.43 (0.15–1.29) 0.132 – –
Concomitant pathology
DM + other (reference)
aMD
1
4.14 (1.46–11.8) 0.008
1
10.3 (1.09–98.2) 0.042
Pseudophakia 0.03 (0–0.21) 0.0005 0.01 (0–0.009) 0.0002
arm
Untreated (reference)
Timogel given the evening before
Timogel given 2 hours before
1
0.87 (0.30–2.47)
0.09 (0.01–0.76)
0.790
0.027
1
0.79 (0.20–3.06)
0.06 (0.01–0.54)
0.735
0.012
Abbreviations: AMD, age-related macular degeneration; CI, confidence interval; DM, diabetes maculopathy; HR, hazard ratio;  – , not included.
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of IVI treatment. Gismondi et al18 prospectively studied 54 
eyes of 54 patients by measuring IOP immediately before 
and 5 seconds, 5, 10, 15, 30, and 60 minutes, and 1 day after 
receiving a ranibizumab IVI: at the seven post-IVI time points, 
IOP was 21 mmHg in 100%, 79.6%, 70.4%, 59.3%, 46.3%, 
20.4%, and 0% of the eyes, respectively, and 30 mmHg in 
88.9%, 29.6%, 16.7%, 7.4%, and 0% of the eyes, respectively. 
Kim et al8 studied 120 eyes of 112 patients (including 20 
glaucomatous patients) who received IVIs of ranibizumab, 
bevacizumab, pegaptanib, or triamcinolone acetonide: mean 
IOP was 44 mmHg (range: 4 to 87 mmHg) immediately after 
the injection, but decreased to 30 mmHg 30 minutes later. 
The changes in the mean IOP from baseline of all the three 
groups in our study were significant at 5 and 60 minutes 
after the injection, and other studies of short-term IOP 
changes have also found that it tends to return to a safe level 
in the majority of patients 10–30 minutes postinjection.7,9,19
The pathogenesis of short-term increases in IOP after 
anti-VEGF IVIs are most directly related to the increase in 
intraocular fluid volume,20 but Gismondi et al also found a 
relationship with a shorter axial length and other potential 
variables influencing IOP which included scleral thickness, 
scleral rigidity, and ocular outflow capacity.21
It has been found that an acute increase in IOP propor-
tionally decreases optic nerve head and juxtapapillary retinal 
blood flow22 and blocks axonal transport to the optic nerve 
head in animal models.23 The implications of these findings 
are not clear but include possible ganglion cell loss, espe-
cially in patients with glaucoma or other optic neuropathies.24 
We believe that IOP spikes can affect the health of the optic 
nerve in subjects with advanced glaucomatous optic neu-
ropathy as previous studies have found that clear visual field 
progression,25 and even the loss of fixation, are associated 
with short-term IOP spikes following cataract surgery.26
There is disagreement in the literature concerning the 
need for paracentesis to prevent IOP spikes1,6,7,9,27–29 because 
it is invasive, unclear whether it should be performed pre- or 
postinjection, and not devoid of risk of the patients (it takes 
longer than an IVI, and complications such as endophthalmi-
tis, lens damage, and cataract are more frequent). Prophylactic 
antiglaucomatous medications may be safer and easier, but 
it is not clear which drug is the most effective, and there is 
no consensus about routine prophylaxis.
The aim of this study was to determine whether the 
prophylactic use of timolol 0.1% gel is effective in reduc-
ing the IOP spikes after a ranibizumab IVI because most of 
Table 3 Patient characteristics
Variable Untreated Timogel given the  
evening before
Timogel given  
2 hours before
P-value
number of patients (n [%]) 50 (33.3) 50 (33.3) 50 (33.3) –
age, years
Mean (±sD)
Min–max
71.4 (±9.6)
44–86
71.6 (±9.5)
49–88
70.3 (±9.2)
53–87
0.78
Female (n [%]) 30 (60.0) 27 (54.0) 26 (52.0) 0.70
Pathology (n [%])
aMD
DM
Other*
34 (68.0)
14 (28.0)
2 (4.0)
31 (62.0)
17 (34.0)
2 (4.0)
30 (60.0)
18 (36.0)
2 (4.0)
0.94
0.69
0.67
–
Pseudophakia (n [%]) 30 (60.0) 32 (64.0) 30 (60.0) 0.89
Notes: *Other: four branch retinal vein occlusion (two control and two timolol 0.1% gel 2 hours before); two central retinal vein occlusion (two timolol 0.1% gel evening 
before).
Abbreviations: aMD, age-related macular degeneration; DM, diabetic maculopathy; min–max, minimum–maximum values; sD, standard deviation; – , not included.
Table 4 intraocular pressure trend over time
Variable Baseline  
mean (±SD)  
min–max
+5 minutes  
mean (±SD)  
min–max
P-value  
(vs baseline)
+60 minutes  
mean (±SD)  
min–max
P-value  
(vs baseline)
Untreated
Timogel given the evening before
P-value (vs control)
Timogel given 2 hours before
15.1 (±1.6) 10–18
15.3 (±1.6) 10–18
0.99
15.5 (±1.9) 8–19
29.3 (±12.0) 15–66
28.3 (±9.9) 16–52
0.69
25.5 (±6.4) 16–54
0.0001
0.0001
18.7 (±5.4) 12–36
18.8 (±5.1) 10–32
0.99
17.3 (±3.9) 10–31
0.0022
0.0031
P-value (vs control) 0.94 0.0078 0.0031 0.49 0.23
Abbreviations: min–max, minimum–maximum values; sD, standard deviation; vs, versus.
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the studies investigating post-IVI IOP do not say whether 
IOP-lowering pretreatment was used or not. This is the first 
study that evaluates the efficacy of prophylactic pressure-
lowering treatment on post-IVI hypertensive spikes of 25 
and 40 mmHg, which are more indicative parameters for 
assessing the risk of post-IVI optic nerve damage than abso-
lute variations in IOP.22–26 To the best of our knowledge, there 
are no previously published studies of the prophylactic use 
of timolol 0.1% gel for this purpose with which our findings 
could be compared.
Ozcaliskan et al30 studied 151 eyes of 151 patients 
to evaluate the effect of topical, fixed-combination of 
dorzolamide/timolol prophylaxis on short-term IOP changes 
in patients who had received a bevacizumab IVI. All the 
post-IVI IOP values were compared between the 75 eyes 
that received prophylaxis and the 76 eyes that were not pre-
treated: there was a significant between-group difference in 
IOP measured 1 minute after IVI (P=0.04) and a statistically 
significant difference between the baseline and all the other 
recorded values, except those measured 60 minutes after 
IVI (P0.05).30
Murray et al31 studied 24 patients with confirmed or sus-
pected glaucoma who received oral acetazolamide 500 mg or 
no treatment 60–90 minutes before a 0.5 mg ranibizumab IVI 
for neovascular age-related macular degeneration, in order to 
determine whether the prophylaxis reduced the incidence and 
duration of post-IVI increases in IOP. The results showed a 
statistically significant reduction in IOP in the treated group, 
but only 30 minutes after the IVI.31
Kim et al32 studied 166 patients (175 eyes) scheduled 
for an anti-VEGF IVI, who were divided into three groups: 
group 1 (53 patients) received dorzolamide/timolol (Cosopt®; 
Merck & Co., Inc.; Kenilworth, NJ, USA) 1 hour before 
the procedure; group 2 (84 patients) received brinzolamide/
timolol (Elazop®; Alcon Laboratories, Inc., Fort Worth, TX, 
USA); and group 3 (29 patients) received no prophylaxis. 
The IOP changes from baseline to 5 and 30 minutes after IVI 
were significant in all the three groups. The three groups were 
subdivided on the basis of whether they had received beva-
cizumab or ranibizumab, and all the six subgroups showed 
significant changes in IOP from baseline to 5 and 30 minutes 
after IVI.32 Unlike the aforementioned first two studies, this 
study did not compare the three groups with each other, but 
only the IOP changes over time in each group.
Frenkel et al33 studied 71 patients with exudative age-
related macular degeneration who received an anti-VEGF IVI 
of pegaptanib, ranibizumab, or bevacizumab. IOP-lowering 
medication was administered 1 hour before injection to 63%, 
74%, and 66%, respectively, of the patients in each IVI group; 
the remaining patients did not receive any prophylaxis. There 
were no statistically significant differences in IOP regardless 
of whether IOP-lowering premedication was used except for 
one interval (3–10 minutes, no medication versus two medi-
cations) in the pegaptanib group.33 The type of prophylactic 
drug used for each patient was not specified, and, as in the 
other three studies, the effectiveness of prophylactic IOP-
lowering therapy on the post-IVI incidence of hypertensive 
spikes of 25 and 40 mmHg was not evaluated, but only 
the variations in IOP.
Timolol 0.1% is a beta-adrenergic antagonist that low-
ers IOP by decreasing the aqueous production of the ciliary 
body.34 It acts for 30–60 minutes after administration35 and, 
as it does not depend on the outflow capacity, it lowers IOP 
significantly even in the early postoperative period. Quaranta 
et al36 have found that both timolol maleate 0.5% solution 
administered twice daily and timolol 0.1% gel instilled once 
Table 5 association with spike 25 mmhg occurrence at any time
Variable Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
age (for each 10-year increase) 0.56 (0.39–0.82) 0.002 1.03 (0.52–2.03) 0.927
sex
Female (reference)
Male
1
0.80 (0.42–1.53) 0.500 – –
Concomitant pathology
DM + other (reference)
aMD
1
1.98 (1.01–3.88) 0.048
1
1.11 (0.39–3.18) 0.838
Pseudophakia 0.20 (0.10–0.42) 0.0001 0.20 (0.07–.056) 0.002
arm
Untreated (reference)
Timogel given the evening before
Timogel given 2 hours before
1
0.73 (0.33–1.59)
0.79 (0.36–1.72)
0.424
0.549
1
0.74 (0.32–1.72)
0.75 (0.32–1.76)
0.478
0.513
Abbreviations: AMD, age-related macular degeneration; CI, confidence interval; DM, diabetes maculopathy; HR, hazard ratio; –, not included.
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a day have similar and significant circadian efficacy and have 
minimal effects on blood pressure and diastolic ocular perfu-
sion pressure in patients with primary open-angle glaucoma. 
Furthermore, many studies have found that timolol 0.1% 
gel is effective after cataract surgery:35,37–39 Lai et al35 and 
Kanellopoulos et al39 showed that it is more effective than 
latanoprost or acetazolamide, respectively, in preventing 
ocular hypertension early after phacoemulsification and 
intraocular lens implantation.
Timolol 0.1% gel is usually instilled once a day, but, 
in order to assess its effectiveness over time, our group 2 
patients instilled the drops the evening before IVI. Instead 
other topical therapies (dorzolamide/timolol or brinzolamide/
timolol) with a shorter duration of action need to be usually 
administered twice a day. Prostaglandin analogs are instilled 
once a day, but are not an option for prophylaxis as they play 
a role in the inflammatory process, which could be one of the 
causes of post-IVI increases in IOP.40 It therefore, seemed to 
us that timolol 0.1% gel would be the most appropriate topical 
prophylactic therapy to reduce post-IVI IOP spikes because 
of its longer duration of action and greater safety.
The trends of IOP were similar in our study groups, with 
higher values being recorded 5 minutes after IVI (Table 4). 
However, only the group that received timolol 2 hours before 
IVI had significantly lower IOP values than the untreated 
group; but, we expected similar results in the group receiving 
timolol the evening before the injection.
We assessed the incidence of clinically significant 
intraocular hypertensive spikes (25 or 40 mmHg) 
because it is more important to evaluate the effectiveness of 
prophylaxis on these rather than on IOP variations, as it is 
thought that they are more hazardous for optic nerve health 
in subjects with glaucoma.22–26 Our multivariate analysis did 
not reveal any significant differences between the control 
and the treated groups in terms of spikes of 25 mmHg, 
but administration of timolol 0.1% only 2 hours before IVI 
was significantly more effective in preventing hypertensive 
spikes of 40 mmHg than no prophylaxis (although, once 
again, we expected similar results in the group receiving 
timolol the evening before the injection).
We did not include patients with glaucoma or ocular 
hypertension, or those being treated with IOP-lowering 
medications (although they may benefit more from such 
prophylactic therapy) because the use of other IOP-lowering 
drugs may have biased the evaluation of the effectiveness 
of timolol prophylaxis. We also considered only IVI-naïve 
patients because a number of studies of small case series have 
found delayed and sometimes persistent ocular hypertension 
occurring several weeks to months after multiple IVIs of 
ranibizumab and/or bevacizumab in patients with exudative 
age-related macular disease.11,41,42
One limitation of this study is the small number of post-
IVI IOP measurements (after 5 and 60 minutes); it would 
have been useful to evaluate IOP over a longer period in 
order to assess the 24-hour efficacy of the prophylactic IOP-
lowering medication.
Conclusion
Our results showed that IOP spikes are a frequent complica-
tion of anti-VEGF IVIs: spikes of 25 mmHg were observed 
at any time in 54% of the patients in group 1, 44% of those in 
group 2, and 48% of those in group 3; and spikes of 40 mmHg 
(only detected 5 minutes after IVI) were observed in 18%, 
16% and 2% of the patients, respectively. The incidence of 
hypertensive IOP 5 minutes after a ranibizumab IVI was 
significantly less in patients who received timolol 0.1% gel 
2 hours before IVI, who also benefited from significantly 
greater protection against spikes 40 mmHg. These findings 
suggest that the routine prophylactic use of timolol 0.1% gel 
2 hours before IVI is a safe and effective means of preventing 
IOP spikes, reducing the need for emergency procedures, and 
preserving the health of the optic nerve.
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